



EANS-Voting Rights: Epigenomics AG
Release of a voting rights announcement
according to article 26, section 1.1 WpHG (Securities Trading Act) with the aim
of a Europe-wide distribution

22.04.2010 - 15:01 Uhr, Epigenomics AG

Notification of voting rights transmitted by euro adhoc. The issuer is
responsible for the content of this announcement.

Person/company obliged to make the notification: ----- Name:
see notification

Place: New York, NY

State: USA Company data:

----- Name: Epigenomics AG

Address: Kleine Präsidentenstraße 1, 10178 Berlin

Place: Berlin

State: Deutschland Voting Rights: Release of a Voting Rights Notification Pursuant to §
26, para.

1 WpHG (German Securities Trading Act) with the Aim of an Europe-wide

Distribution Issuer: Epigenomics AG

Kleine Präsidentenstr. 1

10178 Berlin

Germany Voting Rights Notification: On 21 April 2010, Julian Baker, USA, notified

Epigenomics AG of voting rights

in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22

para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows: On 19 April 2010, the share
of Julian Baker in the voting rights of Epigenomics

AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as

at this date, to 5.12 per cent of the voting rights (i.e., 2,257,212 voting
rights of the 44,092,085 shares outstanding at that date) in Epigenomics AG. All 5.12 per
cent of the voting rights (2,257,212 voting rights) are attributed

to Julian Baker pursuant to Sec. 22 para. 1 sent. 1 no. 1 WpHG through the

following entities controlled by Julian Baker: • Baker Brothers Life Sciences Capital (GP),
LLC

- Baker Brothers Life Sciences Capital, L.P.
- Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212 voting rights) of Baker Brothers Life
Sciences, L.P. are additionally attributed to Julian Baker
pursuant to sec. 22 para. 2 WpHG. Furthermore, on 21 April 2010, Felix Baker, USA, notified
Epigenomics AG of

voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection

with sec. 22 para. 1 sent. 1 no.1 WpHG and sec. 22 para. 2 WpHG as follows: On 19 April
2010, the share of Felix Baker in the voting rights of Epigenomics

AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as

at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights)
in Epigenomics AG. All 5.12 per cent of the voting rights (2,257,212 voting rights) are

attributed to Felix Baker pursuant to sec. 22 para. 1 sent. 1 no.1 WpHG through

the following entities controlled by Felix Baker: • Baker Brothers Life Sciences Capital
(GP), LLC

- Baker Brothers Life Sciences Capital, L.P.
- Baker Brothers Life Sciences, L.P.

All 5.12 per cent of the voting rights (2,257,212 voting rights) of Baker Brothers Life
Sciences, L.P. are additionally attributed to Felix Baker
pursuant to sec. 22 para. 2 WpHG. Furthermore, on 21 April 2010, Baker Brothers Life
Sciences Capital (GP), LLC,

New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG

pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no.

1 WpHG and sec. 22 para. 2 WpHG as follows: On 19 April 2010, the share of Baker Brothers
Life Sciences Capital (GP), LLC

in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of

sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the

voting rights (2,257,212) in Epigenomics AG. 5.00 per cent of the voting rights (2,204,639
voting rights) are attributed to

Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 1

sent. 1 no. 1 WpHG through the following entities controlled by Baker Brothers
Life Sciences Capital (GP), LLC: • Baker Brothers Life Sciences Capital, L.P.

• Baker Brothers Life Sciences, L.P.

0.12 per cent of the voting rights (52,573 voting rights) are attributed to Baker Brothers Life Sciences Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG. Furthermore, on 21 April 2010, Baker Brothers Life Sciences Capital, L.P., New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para. 2 WpHG as follows: On 19 April 2010, the share of Baker Brothers Life Sciences Capital, L.P. in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212) in Epigenomics AG. 5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG through the following entity controlled by Baker Brothers Life Sciences Capital, L.P.: • Baker Brothers Life Sciences, L.P. 0.12 per cent of the voting rights (52,573 voting rights) are attributed to Baker Brothers Life Sciences Capital, L.P. pursuant to sec. 22 para. 2 WpHG. Furthermore, on 21 April 2010, Baker Brothers Life Sciences, L.P., New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 2 WpHG as follows: On 19 April 2010, the share of Baker Brothers Life Sciences, L.P. in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights) in Epigenomics AG. 0.12 per cent of the voting rights (52,573 voting rights) are attributed to Baker Brothers Life Sciences, L.P. pursuant to sec. 22 para. 2 WpHG. Furthermore, on 21 April 2010, 14159 Capital (GP), LLC, New York, NY, USA notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para. 1 sent. 1 no. 1 WpHG and sec. 22 para.2 WpHG as follows: On 19 April 2010, the share of 14159 Capital (GP), LLC in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights) in Epigenomics AG. 0.12 per cent of the voting rights (52,573 voting rights) are attributed to 14159 Capital (GP), LLC pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG. 5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to 14159 Capital (GP), LLC pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P. Furthermore, on 21 April 2010, 14159 Capital, L.P., New York, NY, USA notified Epigenomics AG of voting rights held in Epigenomics AG pursuant to sen. 21 para. 1 WpHG in connection with sen. 22 para. 1 sent. 1 no. 1 WpHG and sen. 22 para.2 WpHG as follows: On 19 April 2010, the share of 14159 Capital, L.P. in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights) in Epigenomics AG. 0.12 per cent of the voting rights (52,573 voting rights) are attributed to 14159 Capital, L.P. pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG. 5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to 14159 Capital, L.P. pursuant to sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P. Furthermore, on 21 April 2010, 14159, L.P., New York, NY, USA, notified Epigenomics AG of voting rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG in connection with sec. 22 para.2 WpHG as follows: On 19 April 2010, the share of 14159, L.P. in the voting rights of Epigenomics AG exceeded the 5 per cent threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 5.12 per cent of the voting rights (2,257,212 voting rights) in Epigenomics AG. 5.00 per cent of the voting rights (2,204,639 voting rights) are attributed to 14159, L.P. pursuant to Sec. 22 para. 2 WpHG through Baker Brothers Life Sciences, L.P. Date of release: 22 April 2010 Epigenomics AG
The Executive Board Contact: Epigenomics AG
Dr. Achim Plum
Senior Vice President Corporate Development
Tel.: +49 (0)30 24345 368
Fax: +49 (0)30 24345 555
Email: achim.plum@epigenomics.com end of announcement euro
adhoc

Further inquiry note:

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade

Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Original text: Epigenomics AG
ISIN: DE000A0BVT96
Digitale Pressemappe: <http://www.presseportal.de/pm/38683/>
Pressemappe via RSS: http://presseportal.de/rss/pm_38683.rss2